We harness the power of machine learning to move beyond experimental screening found in traditional therapeutic antibody discovery and engineering processes. To achieve this, we combine three state-of-the-art techniques in protein engineering: gene editing, deep sequencing, and deep learning. With our proprietary mammalian system and drug discovery workflow, we generate thousands of optimized lead candidates ready for preclinical studies at a fraction of the time and cost.
News
